Quarterly ResultMay 5, 2026, 04:15 PM
Trevi Therapeutics Q1 Net Loss Widens to $13.19M; R&D Up 27%
AI Summary
Trevi Therapeutics reported a net loss of $13.19 million for the first quarter of 2026, an increase from $10.34 million in the same period last year. This was primarily driven by a 27% rise in research and development expenses and a 36% increase in general and administrative expenses. The company's cash and cash equivalents slightly increased to $19.41 million, while marketable securities decreased to $152.37 million.
Key Highlights
- Net loss widened to $13.19 million in Q1 2026 from $10.34 million in Q1 2025.
- Research and development expenses increased 27% to $9.94 million in Q1 2026.
- General and administrative expenses rose 36% to $4.97 million in Q1 2026.
- Total operating expenses grew to $14.91 million in Q1 2026 from $11.47 million in Q1 2025.
- Cash and cash equivalents were $19.41 million as of March 31, 2026.
- Marketable securities totaled $152.37 million as of March 31, 2026.
- Net cash used in operating activities was $16.69 million in Q1 2026.